🔗 Share this article

Given that America proceeds with historic revisions to its immunization schedules, a particular individual appears unexpectedly: Høeg, an American of Danish descent physician and epidemiologist who first made her name by questioning coronavirus shots throughout the global health crisis and has zeroed in on possible deaths after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Schedule

Health officials planned to unveil sweeping changes to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US at odds with many the international standard with little proof for benefit. This reveal has been postponed until the new year.

In place of the director of the vaccine center, Høeg is listed to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for ending certain pediatric shot schedules in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Background

The appointee has no apparent experience in medication creation, oversight or management, which has been customary for past directors of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of CBER would “understand laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who headed the center have had.”

The drug center has an enormous workload at the agency, she pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division approves numerous generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and all of those need to be looked after,” Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership element to the role, which supervises more than 5,000 personnel. “It is a enormous management job, if you execute it properly,” the former official added.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's fitness for the role and whether this appointment represents more teamwork among agency officials on vaccines, a representative responded that the “concerns rely on inaccurate premises”.

“This background matches the functions of her position,” the official explained, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial expedited medication authorization process that reportedly troubled her predecessors. “By what process are these drugs being chosen for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of most medications, except for vaccines.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, past, Howard said. She published a research paper using unconfirmed crowd-sourced reports to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new administration featured changing rules for novel immunizations and discontinuing “optional” vaccines, she stated post-election on a online show. At the FDA, Dr. Høeg has reportedly suggested excluding teenage boys from receiving Covid vaccinations.

“She is an thorough dogmatist who starts off with her preconceived notions and works backwards to accommodate the data in a very disingenuous, dishonest way,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined fellow contrarians, {like|